UroGen Pharma Ltd.
URGN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $90 | $93 | $104 | $172 |
| Short-Term Investments | $37 | $64 | $92 | $65 |
| Receivables | $20 | $20 | $20 | $20 |
| Inventory | $8 | $7 | $8 | $9 |
| Other Curr. Assets | $1 | $1 | $14 | $10 |
| Total Curr. Assets | $169 | $197 | $237 | $276 |
| Property Plant & Equip (Net) | $9 | $6 | $5 | $4 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $5 | $5 | $5 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $7 | $1 | $1 | $1 |
| Total NC Assets | $17 | $12 | $10 | $10 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $185 | $209 | $248 | $286 |
| Liabilities | – | – | – | – |
| Payables | $10 | $14 | $15 | $11 |
| Short-Term Debt | $0 | $0 | $0 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $3 | $3 | $12 | $19 |
| Total Curr. Liab. | $42 | $48 | $42 | $46 |
| LT Debt | $122 | $123 | $122 | $122 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $130 | $129 | $127 | $125 |
| Total NC Liab. | $258 | $255 | $252 | $249 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $8 | $5 | $3 | $2 |
| Total Liabilities | $300 | $302 | $294 | $295 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$933 | -$900 | -$850 | -$806 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | -$0 | $0 | $0 | $0 |
| Total Equity | -$115 | -$93 | -$46 | -$9 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $185 | $209 | $248 | $286 |
| Net Debt | $32 | $30 | $18 | -$50 |